Table 1.
Effects of IFN-γ versus betamethasone 0.1% on the evaluated efficacy measures.
| IFN-γ | P value | Betamethasone 0.1% | P value | |||
|---|---|---|---|---|---|---|
| Pretrial | Posttrial | Pretrial | Posttrial | |||
| DLQI | 20.80 ± 0.88 | 8.20 ± 0.48 | <0.001 | 21.88 ± 0.77 | 17.18 ± 1.28 | <0.001 |
| SCORAD-A | 68.58 ± 4.47 | 29.05 ± 3.67 | <0.001 | 44.15 ± 2.07 | 35.82 ± 2.35 | 0.004 |
| SCORAD-B | 11.35 ± 0.33 | 4.55 ± 0.34 | <0.001 | 9.12 ± 0.57 | 8.29 ± 0.59 | 0.044 |
| SCORAD-C | 16.60 ± 1.03 | 6.10 ± 0.70 | <0.001 | 15.94 ± 0.65 | 15.41 ± 0.84 | >0.05 |
| Objective SCORAD | 53.44 ± 1.16 | 21.73 ± 1.77 | <0.001 | 40.74 ± 1.89 | 36.19 ± 2.01 | 0.006 |
| Overall SCORAD | 71.44 ± 2.45 | 23.95 ± 1.78 | <0.001 | 58.31 ± 1.88 | 51.60 ± 2.75 | 0.006 |
Values are expressed as mean ± SEM. DLQI: dermatology life quality index; SCORAD: scoring atopic dermatitis. SCORAD-A, -B, and -C denote extent, intensity, and subjective symptoms of the disorder, respectively.